Kolon TissueGene, Aiming for DMOAD Designation

Oct 13, 2017

Company: Mirae Asset
Analyst: Taehee Kim

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

Oct 12, 2017

Company: 미래에셋대우
Analyst: 김태희

Kolon TissueGene, Invossa Could Be Osteoarthritis Game-Changer

Sep 26, 2017

Company: Samsung Securities
Analyst: Brian Lee

• « Previous
• 1
• 2
• 3
• 4